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Abstract 
 
Cystic Fibrosis (CF) is the most common fatal hereditary disease among Caucasians, where chronic 
lung infections with the bacterium Pseudomonas aeruginosa are the leading cause of death. In CF, P. 
aeruginosa converts to a mucoid phenotype, causing a decline in patient survival. The most common 
mutations responsible for mucoidy disrupt a gene encoding the anti-sigma factor MucA. MucA-
independent mechanisms contributing to mucoidy have been previously proposed; however, the 
gene(s) responsible remain uncharacterized. As a direct result, mucoid conversion of P. aeruginosa 
remains partially unclear. The aim of this work was to identify and characterize MucA independent 
mucoid conversion pathways. Along the way, we found strong evidence to suggest a MucA-
independent pathway may not exist. First, the mucA gene was sequenced from a collection of 
laboratory-derived mucoid isolates. 20% were found to possess a wild type mucA and these isolates 
were chosen for further investigation into a MucA independent pathway. To confirm that MucA does not 
control alginate overexpression on a protein level, we overproduced MucA on an inducible plasmid. 
However, the mucoid phenotype of all isolates was complemented upon MucA overproduction, 
illustrating that we have yet to isolate mucoid colonies independent of MucA. To this end, we developed 
a plasmid-based screen for mucoid isolates whose phenotype cannot be complemented by MucA 
overproduction. Surprisingly, it remained that this screen yielded only mucoid derivatives with mutations 
in mucA. Despite increasing evidence that MucA is required for mucoid conversion, the previous 
studies suggest a MucA independent pathway exists, which is also independent of the sigma factor 
AlgT/U. Therefore, to elucidate this pathway we screened for mucoid isolates in an algT-deficient strain. 
Unfortunately, four independent mucoid conversion assays with and without sublethal hydrogen 
peroxide treatment resulted in no mucoid isolates. Concerned by these conflicting data, we acquired 
the original muc23 isolate previously published to be independent of MucA and determined that it too is 
complemented by MucA overexpression, demonstrating the importance of investigating post-
transcriptional control of protein expression. These data suggest that MucA alterations are essential for 
mucoid conversion and may be the sole determinant of mucoid conversion in CF patients.  
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Chapter 1: Background 
Pseudomonas aeruginosa lifestyle  
Pseudomonas aeruginosa is an aerobic motile Gram negative rod that is naturally found in soil 
but is ubiquitous in most environments (1). This large range of suitable habitats is made 
possible because the bacterium is able to thrive in hypoxic, anaerobic and nutrient poor 
locations (1). The adaptability, large collection of virulence factors and recalcitrance to 
antibiotics of P. aeruginosa has made it a serious problem within hospitals. This opportunistic 
pathogen causes 11-14% of all nosocomial infections and 13-22% of the infections in intensive 
care unit patients (2). Common infection sites are the urinary tract, catheters and severe burn 
wounds but any immune compromised patient is at risk of infection (3). P. aeruginosa is 
especially dangerous when biofilm growth is established as it develops higher antibiotic 
resistant (1, 4).  Virulence factors that promote infections include type IV pilus, type III secretion, 
exotoxin ExoU, and the pigment pyocyanin. All of these facets of P. aeruginosa make it very 
well suited for Cystic Fibrosis lung infection.  
P. aeruginosa infections in Cystic Fibrosis patients  
Cystic Fibrosis (CF) is the most common fatal inherited disease among Caucasians (5). 
Mutations present in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) cause 
a defect in the mucous membrane chloride ion transport systems.  Chloride ion uptake is 
increased without balance so the mucous produced on the lung inner surface becomes less 
hydrated, more viscous and more difficult for CF patients to clear. This thick mucous layer 
becomes a prime area for bacterial infections allowing a multitude of bacteria to establish 
infections including Haemophilus influenzae and Staphylococcus aureus (6). The continual 
colonization of the CF lung causes a chronic hyper inflammatory state predominated by 
neutrophils leading to increased host cell damage. This damage allows further infection and 
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thereby perpetuates the cycle of infection to inflammation to damage.  Infection with P. 
aeruginosa starts at a very young age (3yrs) but does not become the dominant infection until 
the teen years. Eventually leading to the death of CF patients (5).  This dominance shift is 
correlated with a phenotypic evolution from an initial non mucoid to a mucoid phenotype.  The 
mucoid phenotype is defined by the overproduction of the exopolysaccharide alginate. Alginate 
is a linear copolymer of (1-4) linked β-D-mannuronic acid and α-L-guluronic acid that acts to 
cover the cell in a protective coat (7). Alginate overexpression provides P.aeruginosa protective 
advantage via increased resistance to all available antibiotics and host innate immune factors 
thereby promoting chronic infection (8-12). Mucoid conversion is typically induced by DNA 
mutations resulting in a loss of regulation of alginate. Inflammatory factors which are abundant 
in the CF lung have been shown to induce mucoid conversion (13, 14). Moreover, mucoid P. 
aeruginosa are selected for due to increased resistance. It remains crucial to complete our 
understanding of mucoid conversion to be able to develop therapeutics against chronic P. 
aeruginosa infections.   
Alginate Regulation 
Alginate overexpression is activated by the sigma factor encoded by algT/U (σ22). σ22 modulates 
the production of three proteins (AlgB, AmrZ, and AlgR) that allow expression of the alginate 
biosynthetic operon starting with the algD gene. AlgT is produced from a single operon 
containing the AlgT specific anti-sigma factor MucA (algT-mucA-mucB-mucC-mucD) with five 
promoters ranging from -452 bp to -53 bp upstream (15). MucA regulates the mucoid phenotype 
by binding AlgT. This 175 amino acid protein has one transmembrane domain bridging the 
periplasm and cytoplasm. The MucA cytoplasmic N-terminus binds σ22 sequestering it to the 
inner membrane. This MucA-AlgT interaction is stabilized by MucB binding of MucA’s 
periplasmic C-terminus. When this MucA-AlgT interaction is destabilized alginate is 
overexpressed and the mucoid phenotype is established.  
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  The most common and best characterized mechanism for mucoid conversion is mucA 
mutagenesis. These mutations render MucA nonfunctional and AlgT is no longer sequestered. 
Alginate is overproduced and the isolate maintains a stable mucoid phenotype. This has been 
found to happen in approximately 80% of clinical isolates but in 20%, a wild type (WT) mucA 
gene still remains (6,16,17). It has been previously published (17) that a WT mucA mucoid 
isolate had a stable mutation outside of the mucA locus termed muc23. The specific mutation 
has yet to be characterized. This knowledge is crucial if any therapeutics are to be developed. A 
complete picture of mucoid conversion must be understood to guarantee a safe, useful 
treatment against the phenotypic shift. Previous work has provided insight into the mechanism 
responsible for conversion in the absence of mucA alterations, yet the mutations responsible 
remain elusive (18-21). These mechanisms act post translationally via proteolysis (Fig 1) of 
MucA, destabilizing the MucA-AlgT interaction. The MucA protein is targeted at two sites by two 
separate proteases. The first protease AlgW is activated by excess amounts of MucE in the 
periplasm. MucD, an E. coli protein chaperone homologue, acts in the periplasm to suppress 
AlgW protease activity. Whenever mucD is mutated, AlgW is activated and MucA is degraded 
(Fig 1).  Previous evidence (20) has also shown that a sensor kinase, KinB, helps to decrease 
AlgW activity. When mutations make KinB inactive AlgW degrades MucA (Fig 1). The second 
protease MucP is specific for cleavage of site 2 on MucA and is thought to follow site 1 cleavage 
by AlgW (19). The MucP protease alone has been shown to be sufficient to degrade MucA (19). 
MucP could be independently activated by unidentified stimulators in the absence of functional 
MucD to produce mucoid conversion. The culmination of this work has shown an intricate 
system in place to allow for the cleavage of MucA (Fig 1) but the nature of the muc23 mutation 
and mechanism remains unclear.  
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Figure 1. Regulation of alginate overexpression. Schematic of regulation of MucA stability.  
Disruption of the red regulators (MucABD, KinB) is sufficient to cause mucoid conversion.  
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Sigma factors and alginate overexpression 
Additional insight into MucA-independent mucoid conversion mechanisms has been elucidated 
by investigation into alternative sigma factors able to express alginate. The muc23 isolate has 
been shown to be able to overexpress alginate independent of algT. The RpoN alternative 
sigma factor σ54 was sufficient to maintain the mucoid phenotype when the algT gene was 
mutated (22).  This suggested a novel route to mucoidy as the well-established route flows 
through MucA and AlgT but this strain harbored WT mucA and maintained mucoidy without 
AlgT.  This strain was characterized on varying sodium and nitrogen media to view if the 
nitrogen response sigma factor (RpoN) would alter alginate expression. The muc23 strain 
showed a differential regulation compared to mucA mutated isolates (23), further suggesting 
RpoN involvement. Therefore we sought to characterize these MucA, AlgT independent mucoid 
conversion mechanisms. 
Summary 
P. aeruginosa has proven to be a versatile bacterium and a dangerous opportunistic pathogen. 
This bacterium is a major concern for CF patients where P. aeruginosa infection is the leading 
cause of death (5). The shift from the non mucoid to mucoid phenotype is correlated with a 
severe decline in patient prognosis yet a complete picture of mucoid conversion remains 
elusive. MucA mutations resulting in mucoid conversion have been well characterized, but 
mucoidy independent of mucA remains elusive. Mechanisms involving post transcriptional 
degradation of MucA have been proposed however the specific mutations responsible are 
uncharacterized (18-21). The aim of this project was to identify mutations providing mucoid 
conversion independent of MucA. The recognition of these mutations will enhance our 
understanding of mucoid conversion and will be essential for development of therapeutics 
targeting mucoid conversion.   
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Chapter 2: Materials and Methods 
Bacterial strains and oligonucleotides 
All strains generated in this study were derived from the Pseudomonas aeruginosa strain 
PAO1algD:cat adapted from previous studies (24). The algD:cat transcriptional fusion construct 
was inserted into PAO1 via the nonreplicative mini-CTX vector. The plasmid DNA insertion was 
directed to the neutral attB gene.  Flippase was used to excise DNA between two plasmid borne 
FRT regions. The removal of plasmid DNA is detected with sucrose sacB negative selection. 
Polymerase chain reaction (PCR) and sequencing analysis were used to verify algD:cat was 
correctly inserted.  
  The PAO1algD:catΔalgT strain was constructed by utilizing the pEX18Ap (25) plasmid 
containing the algT deletion construct cloned into it. Chemically competent SM10 Escherichia 
cells were used to mobilize the plasmid into PAO1algD:cat. Plasmid DNA was integrated into 
the PAO1algD:cat genome and directed into the algT gene. Sucrose sacB negative selection 
was utilized to remove the plasmid insertion and the genomic algT. The plasmid DNA loss will 
include genomic algT if the 500 bases upstream and downstream homologously recombine and 
excise the DNA in between. The resulting PAO1algD:catΔalgT was confirmed through PCR 
amplification and sequencing  analysis.   
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Table 1 
Primers              Sequence 
     mucA upF 5'-TGTTGCGGGATGAGATCGAGG-3' 
     mucA dnR 5'-GGGTGGAGAAGCTGCCATTG-3' 
     mucA 1F-21 5'-GGATCTTCCGCGCTCGTGAAG-3' 
 
Table 1. Primers All primers used in this study. 
 
Media and chemicals  
Pseudomonas aeruginosa was grown on 1/2X Pseudomonas Isolation Agar (PIA) at 1.5% agar, 
Luria-Bertani Agar No Salt (LANS) (10g liter-1 tryptone and 5g liter-1 yeast extract) at 1.5% agar 
and Luria-Bertani No Salt (LBNS) liquid culture (10g liter-1 tryptone and 5g liter-1 yeast extract). 
Escherichia coli was grown on Luria-Bertani Agar (LA) (10g liter-1 tryptone, 5g liter-1 yeast 
extract and 5g liter-1 sodium chloride) at 1.5% agar and Luria-Bertani (LB) liquid culture (10g 
liter-1 tryptone, 5g liter-1 yeast extract and 5g liter-1 sodium chloride).  All cultures were incubated 
at 37⁰C for optimal growth. Antibiotic concentrations (when needed) for P. aeruginosa were 100 
μg/ml tetracycline, 300 μg/ml carbenicillin, 250 μg/ml or 50 μg/ml chloramphenicol,  25 μg/ml 
irgasan, and 1 mM H202. Antibiotic concentrations (when needed) for E. coli were 15 μg/ml 
tetracycline, 100 μg/ml carbenicillin, 25 μg/ml irgasan. Sucrose sacB negative selection against 
the sacB gene was carried out with LANS- 5% sucrose incubated at 30⁰C.  
Mucoid conversion assay  
The mucoid conversion assay was developed in the laboratory by Andrea Rockel. 
PAO1algD:cat was grown overnight in 2ml LBNS. A 0.5 mL aliquot of this overnight was then 
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subcultured into 50ml LBNS and grown to OD 0.5. Aliquots of 5mls of culture were centrifuged 
at 30,000 x g and resuspended in PBS with or with H202. The aliquots were incubated at 37⁰C 
for 1 hour and then centrifuged at 30,000 x g. The pellets were resuspended in 5 ml LBNS and 
grown at 37⁰C overnight. Aliquots of 4ml of the overnights were then centrifuged at 30,000 x g 
and concentrated in 1ml LBNS. This concentration was then plated onto 151.0 cm2 
chloramphenicol plates. The plates were incubated for 48 hrs at 37⁰C to select for mucoid 
colonies. All mucoid isolates had mucA PCR amplified by mucA upF and mucA dnR primers at 
least twice. The PCR product alongside two forward primers (mucA upF, mucA 1F-21) and one 
reverse primer (mucA dnR) was submitted to the OSU Comprehensive Cancer Center for 
sequencing analysis. All mucA sequences were derived from the published PAO1 mucA 
sequence (26).  
Complementation analysis 
The generated mucoid PAO1algD:cat isolates had each pHERD20T and pHERD20T-mucA 
transformed separately (27). Chemically competent E. coli SM10 cells were used to mate 
plasmids into collected mucoid isolates (25). The resulting pHERD20T and pHERD20T-mucA 
containing mucoid isolates were patched from single colonies onto PIA then PIA-0.5% 
arabinose and PIA-5% arabinose. The plates were incubated overnight and mucoid phenotype 
was evaluated visually.   
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Chapter 3: Results  
Selection strategy reveals mucoid isolates are dependent on MucA regardless of mucA 
genotype  
To effectively study the mucoid conversion mechanism in P. aeruginosa, a large collection of 
mucoid isolates was needed. As the spontaneous mutation rate of P. aeruginosa from a 
nonmucoid to a mucoid phenotype is very low (10-8), a selection strategy was needed.  Andrea 
Rockel, a former graduate student in the Wozniak lab, developed an antibiotic selection in the P. 
aeruginosa strain PAO1. The algD promoter, which is overexpressed specifically in mucoid 
isolates, was transcriptionally fused to the promoterless gene for chloramphenicol acetyl-
transferase (cat).  This algD:cat construct allows the preferential expression of chloramphenicol 
resistance in mucoid isolates thereby creating antibiotic selection.  
 This selection strategy was utilized to generate a collection of mucoid isolates. It has 
been previously found that mucoid conversion is increased in the presence of human 
inflammatory factors (28). Therefore, to verify the utility of our selection strategy the frequency 
of mucoid conversion in the presence of sublethal H2O2 was examined compared to 
spontaneous mucoid conversion. The number of mucoid colonies on chloramphenicol was 
divided by the total colony forming units (CFUs) to determine the mucoid conversion frequency. 
Treatment with hydrogen peroxide increased the mucoid conversion frequency seven fold 
compared to baseline non-treatment conversion frequency (data not shown).  A large collection 
of mucoid isolates have been generated using this approach and upon PCR amplification and 
sequencing analysis of mucA has shown generation of 20% of isolates with wild type mucA (Fig 
3A).  This supports the validity of the selection as it has been well established that 20% of 
clinical mucoid isolates maintain a wild type (WT) mucA (17,29).  
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The end goal of this project was to apply whole genome sequencing methodologies to a 
group of WT mucA mucoid isolates to genetically define alternative mucoid conversion 
pathways. With this in mind, we utilized pHERD20T-mucA to make PAO1algD:cat diploid for 
mucA with the reasoning that this would allow for identification of mutations in genes 
independent of mucA (Fig 4A). Unexpectedly, no WT mucA mucoid isolates were recovered 
(Fig 4B).This screen yielded mucoid derivatives with independent mucA mutations in both the 
genome and plasmid mucA allele (Fig 4C). The screen selected against any strains affected by 
WT MucA overproduction and unexpectedly both mutated mucA and WT mucA isolates 
reverted. 
AlgT is essential for P. aeruginosa mucoid conversion 
Previous findings (22) in a well characterized WT mucA mucoid isolate with a stable mutation 
outside of the mucA locus (muc23 mutation) have shown that expression of the mucoid 
phenotype can occur independently of σ22 (encoded by algT/U) through the alternative sigma 
factor σ54 (RpoN). We reasoned that these σ54 pathways were potentially MucA independent and 
could be generated by forcing alginate overexpression by σ54.   With this in mind we generated a 
nonpolar, unmarked deletion of the algT/U gene in PAO1algD:cat via allelic exchange. 
PAO1algD:catΔalgT was subjected to four separate mucoid conversion assays with and without 
nonlethal hydrogen peroxide treatment (Fig 5). No mucoid colonies were ever recovered 
suggesting that the gene algT is essential for mucoid conversion.    
 
The muc23 mutation shows dependency on MucA expression 
As all of our screens have failed to identify any MucA independent strains and algT proved to be 
essential for mucoid conversion, the original muc23 strain was obtained from Dr. John Govan 
for characterization. This strain was subjected to the complementation assay and the mucoid 
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phenotype reverted upon MucA overproduction (Fig 6). This suggests that this dependency on 
MucA concentration is not unique to our collected strains. Even with a previously published 
alternative route through σ54 the muc23 mutant strain remained dependent upon MucA.  
All mucoid isolates revert upon MucA overexpression 
In order to verify our MucA dependency findings, the original mucoid conversion assay was 
utilized to build a larger mucoid isolate collection to subject to pHERD20T-mucA 
complementation analysis. A total of 48 mucoid isolates have shown complementation upon 
MucA overproduction regardless of genotype (Fig 3B).  This result reaffirms the previous 
findings of mucoid conversion being determined by MucA.  
Sequencing of mucA shows a wide variety of mutations capable of rendering MucA 
nonfunctional 
Each mucoid isolate generated was subjected to PCR and sequencing analysis of mucA to 
show genotype. This analysis has revealed a large variety of mutations within the gene (Fig 7).  
Each isolate has had the mucA gene amplified by PCR and sequenced analyzed at least twice 
to confirm results. The most substantial group of mutations (27%) were large (>5bp) deletions 
centered in mucA. The majority of these deletions (77%) lead to a predicted early truncation of 
MucA and thus produced a nonfunctional protein.  This was a general trend in that only 15% of 
the total mutations present in mucA could have potentially allowed the protein to be functional. 
The percent of WT mucA isolates only represents 10% which is less than half of what is 
expected (20%). This number is low potentially because half of the isolates were collected in the 
MucA independent screen (Fig 3) that effectively selected against WT mucA isolates. One 
notable mutation missing from the list is mucA22. This is a guanine deletion at 426 in mucA and 
it is the most common mutation (25%) found in isolates from CF patients (30,31). With this is 
mind, the 4% of isolates with a guanine deletion seems a surprisingly small group. This may 
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suggest that there is additional pressure within the CF lung that favors mucA22 mutations that 
was not present in vitro. The array of mutations was wide and varied from published mutations 
(32). The difficulty in obtaining WT mucA and the wide variety of mutations to eliminate mucA 
functionality show the importance of MucA in the mucoid conversion process. 
MucA may be the sole determinant of mucoid conversion 
A total of 5 WT mucA strains have been generated, a successful antibiotic selection strategy 
has been developed and a large collection of mucoid isolates has been collected. An efficient 
screen for WT mucA mucoid isolates remains elusive. The goal of whole genome sequencing 
has not been reached as a large enough collection is yet to be gathered but a key portion of 
mucoid conversion has been revealed nonetheless. The initial screen to efficiently generate WT 
mucA mucoid isolates revealed unexpected results that were further tested to show that all 
mucoid isolates we have tested are dependent on MucA. Even the deletion of algT could not 
force any conversion mechanisms outside of mucA as previously proposed (22). The validation 
of our complementation findings with the well characterized muc23 containing strain PAO579 
shows that MucA dependency is not solely generated in our PAO1algD:cat but exists in 
independent isolates. The data gathered suggest that mucoid conversion may flow solely 
through MucA.  
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Figure 2. Selection strategy to isolate mucoid colonies  A. Schematic of PAO1algD:cat 
construct. B. Flow-chart illustrating the general scheme for isolating mucoid colonies. C. 
Representative input non-mucoid and output mucoid PAO1algD:cat strains. 
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Figure 3. Sequencing and complementation analysis of mucA reveal mucoid isolates 
depend on MucA A. The mucA gene of mucoid isolates obtained via the selection strategy 
described in Fig. 2 was PCR amplified and the sequence determined. The percentage of 
isolates analyzed with mucA mutations (ΔmucA) or without (WT mucA) are indicated.  B. MucA 
was overexpressed on a plasmid under control of an arabinose inducible promoter. 
Representative images are shown of the alginate phenotype when plated on Pseudomonas 
Isolation Agar containing 300 ug/ml Carbenicillin + 0.5% arabinose. 
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Figure 4. Complementation-based screening for MucA-independent mucoid colonies 
produces solely mucA mutations A. Schematic illustrating the overall strategy to identify 
MucA-independent (MucA+) mucoid colonies.  B. Results of MucA-independent screen where 
the alginate phenotype on Pseudomonas Isolation Agar (PIA) containing 300 ug/ml Carbenicillin 
(Cb) + 0.5% arabinose are indicated as the percent mucoid (MucA+) and non-mucoid (MucA-) 
of the total isolates screened (n=25). C. The plasmid from PAO1algD::catpHERDmucA post-
screen was isolated to examine its functionality. pHERDmucA was transformed into PDO300 
and grown on PIA + Cb + 0.5% arabinose, followed by PCR and sequence analysis of mucA on 
the plasmid. 
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Figure 5. Mucoid colonies could not be recovered in an algU/T-deficient background WT 
PAO1algD::cat and PAO1algD::catΔalgU were grown for 12 h +/- 1.0 mM H2O2 and plated on 
250 μg/ml chloramphenical (Cm) to enumerate the mucoid colony forming units (CFU) and on 
non-selective media to enumerate the total CFU. The mucoid CFU were divided by the total 
CFU to determine the mucoid conversion frequency. Experiments were performed in triplicate 
on four independent occasions and mucoid colonies were never observed in the algU-deficent 
strain. *Indicate a statistically significant difference (P ≤ 0.05) relative to PAO1algD::cat + PBS 
using a student’s t-test. 
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Figure 6. Isolates previously suggested to be mucA-independent are complemented by 
MucA overexpression MucA was overexpressed on a plasmid under control of an arabinose 
inducible promoter. Representative images are shown of the alginate phenotype when isolates 
are plated on Pseudomonas Isolation Agar containing 300 ug/ml Carbenicillin + 0.5% arabinose 
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Figure 7. Sequencing of mucA shows a wide variety of mutations capable of rendering 
MucA nonfunctional Complete collection of genotypic analysis of stable mucoid isolates used 
for this project. Each mucA gene has been PCR amplified and sequenced at least twice to 
ensure results. n=48 
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Chapter 4: Discussion 
The leading cause of mortality in Cystic Fibrosis patients is chronic infection with Pseudomonas 
aeruginosa (5).  The shift to mucoidy is correlated directly with a severe drop in patient 
prognosis yet mucoid conversion mechanisms remain partially unclear. The goal of this project 
was to better understand mucoid conversion by defining novel mechanisms outside of mucA 
mutations.  It has been previously published that stable mutations outside of the mucA locus 
(muc23) can produce mucoid isolates (17). With this in mind the aim of the project was to 
employ whole genome sequencing methods of WT mucA mucoid isolates that were 
independent of MucA. Along the way, four lines of strong evidence were gathered that 
suggested mucoid conversion is solely dependent on MucA. First, all isolates gathered were 
complemented upon MucA overexpression. Second, a screen to find MucA independent mucoid 
isolates failed to generate even one. Third, deletion of algT has shown it to be essential for 
mucoid conversion as no mucoid PAO1algD:catΔalgT isolates were recovered from the mucoid 
conversion assay. Fourth and finally, complementation analysis of the muc23 isolate has shown 
MucA dependent reversion of mucoidy. All of the evidence gathered in this study has suggested 
that MucA alteration may account for all mucoid conversion events.  
 The future directions to find the mucoid conversion mechanisms of WT mucA mucoid 
isolates lie within elucidation of MucA alteration. There have been multiple previously published 
(18-21) mechanisms outside of mucA mutations to cause mucoid conversion. The other 
mechanisms primarily revolve around mutations that activate proteases (AlgW, MucP) to 
degrade MucA and release alginate overexpression. To view if these mutations are present in 
the WT mucA mucoid isolates, the kinB and mucD genes could be PCR amplified and sequence 
analyzed.  Directed laboratory mutations in either gene have been demonstrated to be sufficient 
to cause mucoid conversion; however, it has yet to be determined if these mutations occur in 
CF patients. (18-21). Mutations within kinB are thought to cause a derepression of periplasmic 
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activators of AlgW. Nonfunctional MucD allows the buildup of periplasmic factors that can either 
induce both AlgW and MucP or just MucP proteolysis independently (19). More directly we 
could knockout either the AlgW or MucP proteases in our WT mucA mucoid isolates to 
determine their involvement in MucA stability.  We have uncovered that the mucoid phenotype 
of each of these WT mucA isolates relies on the cellular concentration of MucA.  To further 
confirm these finding we can analyze the amount of MucA present, the amount of MucA 
transcribed and translated, and visualize MucA to view potential degradation. It still remains that 
the group of WT mucA isolates could be applied to whole genome sequencing analysis to give a 
global view of all mutations present. Regardless of the mechanism, we have shown evidence 
that mucoid conversion must flow through MucA alteration. This implies that future studies may 
now fully focus on the MucA protein to understand any mucoid isolate.  
 This project has generated a lot of critical findings but much remains to be finished. The 
biggest step yet to be taken is analysis of clinical strains. It needs to be determined whether 
mucoid conversion is MucA dependent inside the CF lung. We have analyzed 30 mucoid 
isolates from CF patients, which we have determined all are dependent upon MucA. A reliable 
animal model may also provide useful to generate WT mucA mucoid isolate collection but one 
does not currently exist. Utilizing selective pressures such as inflammatory factors abundantly 
present in the CF lung could help in generating more clinically relevant mutations. No treatment 
was used in the conversion assays in an effort to reduce background mutations in the gathered 
WT mucA mucoid isolates to allow for easier whole genomic analysis.    
 The evidence gathered in this project has relied heavily on the overproduction of MucA 
from the pHERD20T-mucA plasmid. The levels of MucA being produced will need to be 
measured to ensure that our complementation results have not been generated as a result of 
MucA protein overwhelming any other mechanism present. We have attempted to address this 
caveat by performing our complementation assay on minimal inducing arabinose (0.5%) and 
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ten-fold higher (5%) as pHERD20T-mucA MucA production is arabinose dose dependent. The 
two arabinose concentrations did not show any differences. This concern could be addressed in 
the future by utilizing a lower copy plasmid and finding the lowest production of MucA to result in 
complementation. If MucA overproduction is found to be overwhelming the mechanisms present 
in the WT mucA mucoid isolates then MucA independent pathways may yet be identified.  
  Another potential caution is that we could not produce a mucoid isolate that lacked algT 
whereas the muc23 strain has been published to remain mucoid upon algT mutagenesis (22). 
The algT gene was disrupted but not completely removed and mutagenesis came after mucoid 
conversion. We have attempted to make a nonpolar, unmarked algT deletion in the muc23 
strain but we were unsuccessful on numerous attempts. It may be that some portion of AlgT 
needs to remain intact in the cell to allow the muc23 mutation to be nonlethal. This is 
understandable when it is noted that σ22 is essential in E. coli (33). Also, technically this deletion 
is difficult to achieve as it is a rare double recombination event with a weak negative selection. 
Further analysis will need to be done to understand this necessity for algT in both maintenance 
of and conversion to the mucoid phenotype. 
  The sequencing analysis performed uncovered the fact that the mutations present in 
mucA do not contain mucA22. This is troubling as this is the most frequent mucA mutation 
identified in clinical isolates from CF patients (30,31). The conversion assay may need to be 
altered to better reflect CF lung selective pressures to gather more clinically relevant mutations.   
 The evidence gathered thus far has allowed us to shed more light on the phenotypic shift 
that is correlated with chronic infection. We have identified the single protein that must be 
altered in order to allow the mucoid phenotype and identified a sigma factor essential for 
conversion to the phenotype. These findings alongside previous proteolysis studies have helped 
to more completely elucidate the mechanism for mucoid conversion outside of mucA mutations. 
29 
 
The initial goal of this study was to find any mucoid mechanism independent of mucA in the 
thought that if treatment were developed for mucA dependent mechanisms it would only divert 
down a separate pathway. This study has found no other pathway suggesting that therapeutics 
targeted at MucA will not generate mucoid conversion through separate pathways. MucA may 
now be a useful and more importantly safe target for therapeutics. This work, reinforcing post 
translational alterations of MucA, has brought us closer to a complete understanding of mucoid 
conversion and a great potential target for therapeutics.   
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